Published in Cell Signal on May 18, 2008
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev (2013) 2.42
μ-opioid receptors: correlation of agonist efficacy for signalling with ability to activate internalization. Mol Pharmacol (2010) 1.83
Ligand-directed c-Jun N-terminal kinase activation disrupts opioid receptor signaling. Proc Natl Acad Sci U S A (2010) 1.63
Functional selectivity at the μ-opioid receptor: implications for understanding opioid analgesia and tolerance. Pharmacol Rev (2011) 1.61
Agonist-selective patterns of µ-opioid receptor phosphorylation revealed by phosphosite-specific antibodies. Br J Pharmacol (2011) 1.40
mu-Opioid receptor agonists differentially regulate the expression of miR-190 and NeuroD. Mol Pharmacol (2009) 1.18
Agonist-selective signaling of G protein-coupled receptor: mechanisms and implications. IUBMB Life (2010) 1.14
Deciphering µ-opioid receptor phosphorylation and dephosphorylation in HEK293 cells. Br J Pharmacol (2012) 1.13
Endomorphin-2: a biased agonist at the μ-opioid receptor. Mol Pharmacol (2012) 1.10
Palmitoylation and membrane cholesterol stabilize μ-opioid receptor homodimerization and G protein coupling. BMC Cell Biol (2012) 1.10
How to design an opioid drug that causes reduced tolerance and dependence. Ann Neurol (2010) 1.09
Agonist-dependent mu-opioid receptor signaling can lead to heterologous desensitization. Cell Signal (2010) 1.03
Modulating micro-opioid receptor phosphorylation switches agonist-dependent signaling as reflected in PKCepsilon activation and dendritic spine stability. J Biol Chem (2011) 1.00
Identification of phosphorylation sites in the COOH-terminal tail of the μ-opioid receptor. J Neurochem (2012) 0.93
Non-Coding RNAs Regulating Morphine Function: With Emphasis on the In vivo and In vitro Functions of miR-190. Front Genet (2012) 0.89
GRK2 protein-mediated transphosphorylation contributes to loss of function of μ-opioid receptors induced by neuropeptide FF (NPFF2) receptors. J Biol Chem (2012) 0.88
The influences of reproductive status and acute stress on the levels of phosphorylated mu opioid receptor immunoreactivity in rat hippocampus. Front Endocrinol (Lausanne) (2011) 0.86
Cholesterol level influences opioid signaling in cell models and analgesia in mice and humans. J Lipid Res (2012) 0.84
Analgesic synergy between opioid and α2 -adrenoceptors. Br J Pharmacol (2014) 0.81
FK506-binding protein 12 modulates μ-opioid receptor phosphorylation and protein kinase C(ε)-dependent signaling by its direct interaction with the receptor. Mol Pharmacol (2013) 0.80
Role of FK506 binding protein 12 in morphine-induced μ-opioid receptor internalization and desensitization. Neurosci Lett (2014) 0.79
MicroRNAs Are Involved in the Development of Morphine-Induced Analgesic Tolerance and Regulate Functionally Relevant Changes in Serpini1. Front Mol Neurosci (2016) 0.78
ßarrestin1-biased agonism at human δ-opioid receptor by peptidic and alkaloid ligands. Cell Signal (2011) 0.78
Posttranslation modification of G protein-coupled receptor in relationship to biased agonism. Methods Enzymol (2013) 0.77
Opioid receptor trafficking and signaling: what happens after opioid receptor activation? Cell Mol Neurobiol (2011) 0.77
G Protein-Coupled Receptor Kinase 2 (GRK2) and 5 (GRK5) Exhibit Selective Phosphorylation of the Neurotensin Receptor in Vitro. Biochemistry (2015) 0.76
Spinal or supraspinal phosphorylation deficiency at the MOR C-terminus does not affect morphine tolerance in vivo. Pharmacol Res (2017) 0.75
Thapsigargin, a tumor promoter, discharges intracellular Ca2+ stores by specific inhibition of the endoplasmic reticulum Ca2(+)-ATPase. Proc Natl Acad Sci U S A (1990) 13.34
Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. Nature (1996) 7.15
The role of beta-arrestins in the termination and transduction of G-protein-coupled receptor signals. J Cell Sci (2002) 5.04
G protein-coupled receptors. III. New roles for receptor kinases and beta-arrestins in receptor signaling and desensitization. J Biol Chem (1998) 4.37
Mu-opioid receptor desensitization by beta-arrestin-2 determines morphine tolerance but not dependence. Nature (2000) 3.42
Opiate receptor knockout mice define mu receptor roles in endogenous nociceptive responses and morphine-induced analgesia. Proc Natl Acad Sci U S A (1997) 3.26
Functional dissociation of mu opioid receptor signaling and endocytosis: implications for the biology of opiate tolerance and addiction. Neuron (1999) 3.15
A beta-arrestin/green fluorescent protein biosensor for detecting G protein-coupled receptor activation. J Biol Chem (1997) 3.12
Role for G protein-coupled receptor kinase in agonist-specific regulation of mu-opioid receptor responsiveness. Proc Natl Acad Sci U S A (1998) 3.07
Endocytosis of the mu opioid receptor reduces tolerance and a cellular hallmark of opiate withdrawal. Neuron (2001) 2.96
Molecular mechanisms and regulation of opioid receptor signaling. Annu Rev Pharmacol Toxicol (2000) 2.95
Arrestin interactions with G protein-coupled receptors. Direct binding studies of wild type and mutant arrestins with rhodopsin, beta 2-adrenergic, and m2 muscarinic cholinergic receptors. J Biol Chem (1995) 2.55
Morphine-activated opioid receptors elude desensitization by beta-arrestin. Proc Natl Acad Sci U S A (1998) 2.45
Regulation of opioid receptor trafficking and morphine tolerance by receptor oligomerization. Cell (2002) 2.40
Differential mechanisms of morphine antinociceptive tolerance revealed in (beta)arrestin-2 knock-out mice. J Neurosci (2002) 2.01
Reduced development of tolerance to the analgesic effects of morphine and clonidine in PKC gamma mutant mice. Pain (2001) 1.97
Phosphorylation and agonist-specific intracellular trafficking of an epitope-tagged mu-opioid receptor expressed in HEK 293 cells. J Neurochem (1995) 1.93
Agonist-selective mechanisms of mu-opioid receptor desensitization in human embryonic kidney 293 cells. Mol Pharmacol (2006) 1.87
mu-Opioid receptors: Ligand-dependent activation of potassium conductance, desensitization, and internalization. J Neurosci (2002) 1.81
Morphine induces terminal micro-opioid receptor desensitization by sustained phosphorylation of serine-375. EMBO J (2004) 1.77
Targeted construction of phosphorylation-independent beta-arrestin mutants with constitutive activity in cells. J Biol Chem (1999) 1.69
Mu-opioid receptor desensitization: is morphine different? Br J Pharmacol (2004) 1.64
Phosphorylation of Ser363, Thr370, and Ser375 residues within the carboxyl tail differentially regulates mu-opioid receptor internalization. J Biol Chem (2001) 1.46
Agonist induced homologous desensitization of mu-opioid receptors mediated by G protein-coupled receptor kinases is dependent on agonist efficacy. Mol Pharmacol (1998) 1.43
Determination of the role of conventional, novel and atypical PKC isoforms in the expression of morphine tolerance in mice. Pain (2006) 1.37
Beta-arrestin2 and c-Src regulate the constitutive activity and recycling of mu opioid receptors in dorsal root ganglion neurons. J Neurosci (2007) 1.30
Mu-opioid receptor desensitization: role of receptor phosphorylation, internalization, and representation. J Biol Chem (2003) 1.25
G-protein receptor kinase 3 (GRK3) influences opioid analgesic tolerance but not opioid withdrawal. Br J Pharmacol (2003) 1.23
Differential mu opiate receptor phosphorylation and desensitization induced by agonists and phorbol esters. J Biol Chem (1996) 1.23
A mitogen-activated protein kinase pathway is required for mu-opioid receptor desensitization. J Biol Chem (1998) 1.22
Receptor density and recycling affect the rate of agonist-induced desensitization of mu-opioid receptor. Mol Pharmacol (2000) 1.22
Desensitization of the isolated beta 2-adrenergic receptor by beta-adrenergic receptor kinase, cAMP-dependent protein kinase, and protein kinase C occurs via distinct molecular mechanisms. Biochemistry (1992) 1.19
Mu and delta opioid receptors are differentially desensitized by the coexpression of beta-adrenergic receptor kinase 2 and beta-arrestin 2 in xenopus oocytes. J Biol Chem (1997) 1.19
Morphine-Induced mu-opioid receptor desensitization. Mol Pharmacol (2005) 1.18
Threonine 180 is required for G-protein-coupled receptor kinase 3- and beta-arrestin 2-mediated desensitization of the mu-opioid receptor in Xenopus oocytes. J Biol Chem (2000) 1.12
mu-Opioid receptor down-regulation and cAMP-dependent protein kinase phosphorylation in a mouse model of chronic morphine tolerance. Brain Res Mol Brain Res (1998) 1.08
Chronic morphine treatment increases cyclic AMP-dependent protein kinase activity in the rat locus coeruleus. Mol Pharmacol (1988) 1.06
Involvement of mitogen-activated protein kinase in agonist-induced phosphorylation of the mu-opioid receptor in HEK 293 cells. J Neurochem (2000) 1.05
PKC and PKA inhibitors reinstate morphine-induced behaviors in morphine tolerant mice. Pharmacol Res (2006) 1.02
Increased response to morphine in mice lacking protein kinase C epsilon. Genes Brain Behav (2006) 1.02
mu-Opioid receptors desensitize less rapidly than delta-opioid receptors due to less efficient activation of arrestin. J Biol Chem (2002) 0.99
Coincident signalling between the Gi/Go-coupled delta-opioid receptor and the Gq-coupled m3 muscarinic receptor at the level of intracellular free calcium in SH-SY5Y cells. J Neurochem (2001) 0.97
Opioids mobilize calcium from inositol 1,4,5-trisphosphate-sensitive stores in NG108-15 cells. J Neurosci (1994) 0.97
Desensitization of the delta-opioid receptor correlates with its phosphorylation in SK-N-BE cells: involvement of a G protein-coupled receptor kinase. J Neurochem (1998) 0.96
Influence of chronic morphine treatment on protein kinase C activity: comparison with butorphanol and implication for opioid tolerance. Brain Res (1994) 0.95
Opioid receptor types selectively cointernalize with G protein-coupled receptor kinases 2 and 3. J Pharmacol Exp Ther (2002) 0.95
The absence of a direct correlation between the loss of [D-Ala2, MePhe4,Gly5-ol]Enkephalin inhibition of adenylyl cyclase activity and agonist-induced mu-opioid receptor phosphorylation. J Biol Chem (1999) 0.94
delta- and mu-opioid receptor mobilization of intracellular calcium in SH-SY5Y human neuroblastoma cells. Br J Pharmacol (1996) 0.94
Molecular basis for subtype-specific desensitization of inhibitory adenosine receptors. Analysis of a chimeric A1-A3 adenosine receptor. J Biol Chem (1996) 0.93
Phosphorylation of Gi alpha 2 attenuates inhibitory adenylyl cyclase in neuroblastoma/glioma hybrid (NG-108-15) cells. J Biol Chem (1994) 0.92
Tyrosine phosphorylation of the delta-opioid receptor. Evidence for its role in mitogen-activated protein kinase activation and receptor internalization*. Biochem Pharmacol (2000) 0.91
PKC and PKA inhibitors reverse tolerance to morphine-induced hypothermia and supraspinal analgesia in mice. Eur J Pharmacol (2004) 0.89
Phosphorylation of four amino acid residues in the carboxyl terminus of the rat somatostatin receptor subtype 3 is crucial for its desensitization and internalization. J Biol Chem (1997) 0.89
Phosphorylation of Galphas influences its association with the micro-opioid receptor and is modulated by long-term morphine exposure. Mol Pharmacol (2007) 0.87
Mutation of tyrosine 318 (Y318F) in the delta-opioid receptor attenuates tyrosine phosphorylation, agonist-dependent receptor internalization, and mitogen-activated protein kinase activation. Brain Res Mol Brain Res (2000) 0.86
Tyrosine phosphorylation of the mu-opioid receptor regulates agonist intrinsic efficacy. Mol Pharmacol (2001) 0.86
Delta-opioid-induced liberation of Gbetagamma mobilizes Ca2+ stores in NG108-15 cells. Mol Pharmacol (1999) 0.85
delta-Opioid receptors are more efficiently coupled to adenylyl cyclase than to L-type Ca(2+) channels in transfected rat pituitary cells. J Pharmacol Exp Ther (2000) 0.85
Phosphorylation of the G protein gamma12 subunit regulates effector specificity. J Biol Chem (1998) 0.83
Contribution of phospholipase C-beta3 phosphorylation to the rapid attenuation of opioid-activated phosphoinositide response. Mol Pharmacol (1998) 0.82
Co-incident signalling between mu-opioid and M3 muscarinic receptors at the level of Ca2+ release from intracellular stores: lack of evidence for Ins(1,4,5)P3 receptor sensitization. Biochem J (2003) 0.81
Translating the A1C assay into estimated average glucose values. Diabetes Care (2008) 11.55
The US National Comorbidity Survey Replication (NCS-R): design and field procedures. Int J Methods Psychiatr Res (2004) 10.47
Epidemiological serosurvey of hepatitis B in China--declining HBV prevalence due to hepatitis B vaccination. Vaccine (2009) 6.30
Clinical calibration of DSM-IV diagnoses in the World Mental Health (WMH) version of the World Health Organization (WHO) Composite International Diagnostic Interview (WMHCIDI). Int J Methods Psychiatr Res (2004) 6.04
MAVS forms functional prion-like aggregates to activate and propagate antiviral innate immune response. Cell (2011) 5.91
Glucose levels and risk of dementia. N Engl J Med (2013) 4.95
[Human natural infection of Plasmodium knowlesi]. Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi (2006) 3.99
Pancreatic ductal adenocarcinoma: long-term survival does not equal cure. Surgery (2012) 3.87
CD4 decline and incidence of opportunistic infections in Cape Town, South Africa: implications for prophylaxis and treatment. J Acquir Immune Defic Syndr (2006) 3.39
Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol (2012) 3.36
Ghrelin stimulation of growth hormone release and appetite is mediated through the growth hormone secretagogue receptor. Proc Natl Acad Sci U S A (2004) 2.99
Dimorphic effects of Notch signaling in bone homeostasis. Nat Med (2008) 2.82
Evaluation of the impact of hepatitis B vaccination among children born during 1992-2005 in China. J Infect Dis (2009) 2.62
Optimizing resource allocation in United States AIDS drug assistance programs. Clin Infect Dis (2006) 2.45
Presenilin couples the paired phosphorylation of beta-catenin independent of axin: implications for beta-catenin activation in tumorigenesis. Cell (2002) 2.37
The effect of angiotensin-blocking agents on liver fibrosis in patients with hepatitis C. Liver Int (2009) 2.33
Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J (2008) 2.30
Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Abeta 42 production. Proc Natl Acad Sci U S A (2002) 2.29
Opioid-induced tolerance and dependence in mice is modulated by the distance between pharmacophores in a bivalent ligand series. Proc Natl Acad Sci U S A (2005) 2.29
Efficacy and safety of gemcitabine, oxaliplatin, and bevacizumab in advanced biliary-tract cancers and correlation of changes in 18-fluorodeoxyglucose PET with clinical outcome: a phase 2 study. Lancet Oncol (2009) 2.23
Defective neuromuscular synapses in mice lacking amyloid precursor protein (APP) and APP-Like protein 2. J Neurosci (2005) 2.21
Exercise-induced ST-segment elevation in ECG lead aVR is a useful indicator of significant left main or ostial LAD coronary artery stenosis. JACC Cardiovasc Imaging (2011) 2.21
A negative feedback loop of transcription factors that controls stem cell pluripotency and self-renewal. FASEB J (2006) 2.17
Hepatitis C virus infection and its clearance alter circulating lipids: implications for long-term follow-up. Hepatology (2009) 2.13
Unidirectional cross-activation of GRPR by MOR1D uncouples itch and analgesia induced by opioids. Cell (2011) 2.13
A comparative effectiveness analysis of three continuous glucose monitors. Diabetes Care (2012) 1.97
Lapsing during sleep deprivation is associated with distributed changes in brain activation. J Neurosci (2008) 1.92
The effects of isoflurane and desflurane on cognitive function in humans. Anesth Analg (2011) 1.88
Acupuncture for migraine prophylaxis: a randomized controlled trial. CMAJ (2012) 1.87
Comparison of positron emission tomography measurement of adenosine-stimulated absolute myocardial blood flow versus relative myocardial tracer content for physiological assessment of coronary artery stenosis severity and location. JACC Cardiovasc Imaging (2009) 1.84
A novel tool for the assessment of pain: validation in low back pain. PLoS Med (2009) 1.75
Proof-of-concept, randomized, controlled clinical trial of Bacillus-Calmette-Guerin for treatment of long-term type 1 diabetes. PLoS One (2012) 1.74
Non-high-density lipoprotein cholesterol as a biomarker for nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol (2012) 1.74
The anesthetic considerations of tracheobronchial foreign bodies in children: a literature review of 12,979 cases. Anesth Analg (2010) 1.74
Mortality on Mount Everest, 1921-2006: descriptive study. BMJ (2008) 1.66
Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. J Neurosci (2009) 1.65
Presenilin 1 mediates the turnover of telencephalin in hippocampal neurons via an autophagic degradative pathway. J Cell Biol (2004) 1.65
GB virus C (GBV-C) infection in hepatitis C virus (HCV)/HIV-coinfected patients receiving HCV treatment: importance of the GBV-C genotype. J Infect Dis (2006) 1.64
Predictors of antiretroviral treatment failure in an urban HIV clinic. J Acquir Immune Defic Syndr (2007) 1.61
Phase 1/2 study of everolimus in advanced hepatocellular carcinoma. Cancer (2011) 1.59
Beta-arrestin-dependent mu-opioid receptor-activated extracellular signal-regulated kinases (ERKs) Translocate to Nucleus in Contrast to G protein-dependent ERK activation. Mol Pharmacol (2007) 1.56
Structural basis for the prion-like MAVS filaments in antiviral innate immunity. Elife (2014) 1.56
Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther (2010) 1.56
Accelerated plaque accumulation, associative learning deficits, and up-regulation of alpha 7 nicotinic receptor protein in transgenic mice co-expressing mutant human presenilin 1 and amyloid precursor proteins. J Biol Chem (2002) 1.54
Local extension at the hilum region is associated with worse long-term survival in stage I non-small cell lung cancers. Ann Thorac Surg (2011) 1.53
A replicable method for blood glucose control in critically Ill patients. Crit Care Med (2008) 1.50
Bcr-abl signals to desensitize chronic myeloid leukemia cells to IFNα via accelerating the degradation of its receptor. Blood (2011) 1.49
Sequential introduction of reprogramming factors reveals a time-sensitive requirement for individual factors and a sequential EMT-MET mechanism for optimal reprogramming. Nat Cell Biol (2013) 1.47
Metastatic tumors in the pancreas in the modern era. J Am Coll Surg (2010) 1.45
Associations between features of glucose exposure and A1C: the A1C-Derived Average Glucose (ADAG) study. Diabetes (2010) 1.45
Physiological functions of APP family proteins. Cold Spring Harb Perspect Med (2012) 1.44
Distinct rates of palmitate turnover on membrane-bound cellular and oncogenic H-ras. J Biol Chem (2003) 1.43
DTNBP1, a schizophrenia susceptibility gene, affects kinetics of transmitter release. J Cell Biol (2008) 1.42
Obesity and mortality risk: new findings from body mass index trajectories. Am J Epidemiol (2013) 1.42
Triple plasty of bronchus, pulmonary artery, and superior vena cava for non-small cell lung cancer. Ann Thorac Surg (2012) 1.42
In vivo axonal transport rates decrease in a mouse model of Alzheimer's disease. Neuroimage (2007) 1.41
Presenilins are required for the formation of comma- and S-shaped bodies during nephrogenesis. Development (2003) 1.40
Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc Natl Acad Sci U S A (2010) 1.38
Pancreatic fistula rates after 462 distal pancreatectomies: staplers do not decrease fistula rates. J Gastrointest Surg (2008) 1.38
Wild-type presenilin 1 protects against Alzheimer disease mutation-induced amyloid pathology. J Biol Chem (2006) 1.37
Agonist-selective signaling is determined by the receptor location within the membrane domains. Proc Natl Acad Sci U S A (2008) 1.36
Axonal mRNA transport and localized translational regulation of kappa-opioid receptor in primary neurons of dorsal root ganglia. Proc Natl Acad Sci U S A (2006) 1.35
Presenilin-1 regulates intracellular trafficking and cell surface delivery of beta-amyloid precursor protein. J Biol Chem (2002) 1.34
Mu-opioid receptors modulate the stability of dendritic spines. Proc Natl Acad Sci U S A (2005) 1.34
Modulation of gamma-secretase specificity using small molecule allosteric inhibitors. Proc Natl Acad Sci U S A (2009) 1.34
Heterodimerization of mu- and delta-opioid receptors occurs at the cell surface only and requires receptor-G protein interactions. J Biol Chem (2005) 1.34
Spinal G-protein-gated potassium channels contribute in a dose-dependent manner to the analgesic effect of mu- and delta- but not kappa-opioids. J Neurosci (2005) 1.33
Presenilin 1 regulates epidermal growth factor receptor turnover and signaling in the endosomal-lysosomal pathway. J Biol Chem (2007) 1.32
Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy. Curr Med Chem Anticancer Agents (2005) 1.32
[A sero-epidemiological study on hepatitis C in China]. Zhonghua Liu Xing Bing Xue Za Zhi (2011) 1.32
Hepatic steatosis is associated with increased frequency of hepatocellular carcinoma in patients with hepatitis C-related cirrhosis. Cancer (2007) 1.30
miR-211 is a prosurvival microRNA that regulates chop expression in a PERK-dependent manner. Mol Cell (2012) 1.27
Evidence of endogenous mu opioid receptor regulation by epigenetic control of the promoters. Mol Cell Biol (2007) 1.25
Mu-opioid receptor desensitization: role of receptor phosphorylation, internalization, and representation. J Biol Chem (2003) 1.25
SynDB: a Synapse protein DataBase based on synapse ontology. Nucleic Acids Res (2006) 1.25
Super high threshold percolative ferroelectric/ferrimagnetic composite ceramics with outstanding permittivity and initial permeability. Angew Chem Int Ed Engl (2009) 1.23
Hepatitis B screening, prophylaxis and re-activation in the era of rituximab-based chemotherapy. Liver Int (2010) 1.22
Epigenetic programming of mu-opioid receptor gene in mouse brain is regulated by MeCP2 and Brg1 chromatin remodelling factor. J Cell Mol Med (2008) 1.21
Adenylyl cyclase superactivation induced by long-term treatment with opioid agonist is dependent on receptor localized within lipid rafts and is independent of receptor internalization. Mol Pharmacol (2006) 1.21
Hydrodynamic limb vein injection of adeno-associated virus serotype 8 vector carrying canine myostatin propeptide gene into normal dogs enhances muscle growth. Hum Gene Ther (2009) 1.21
Suppression of cyclin-dependent kinase 5 activation by amyloid precursor protein: a novel excitoprotective mechanism involving modulation of tau phosphorylation. J Neurosci (2005) 1.21
Amyolid precursor protein mediates presynaptic localization and activity of the high-affinity choline transporter. Proc Natl Acad Sci U S A (2007) 1.21
Pen2 and presenilin-1 modulate the dynamic equilibrium of presenilin-1 and presenilin-2 gamma-secretase complexes. J Biol Chem (2008) 1.20
Poly(C)-binding proteins as transcriptional regulators of gene expression. Biochem Biophys Res Commun (2009) 1.20
Amyloid precursor protein regulates Cav1.2 L-type calcium channel levels and function to influence GABAergic short-term plasticity. J Neurosci (2009) 1.20
Morphine regulates dopaminergic neuron differentiation via miR-133b. Mol Pharmacol (2010) 1.18
mu-Opioid receptor agonists differentially regulate the expression of miR-190 and NeuroD. Mol Pharmacol (2009) 1.18
Reduced synaptic vesicle density and active zone size in mice lacking amyloid precursor protein (APP) and APP-like protein 2. Neurosci Lett (2005) 1.17
Assembly of a beta2-adrenergic receptor--GluR1 signalling complex for localized cAMP signalling. EMBO J (2009) 1.16
Regulation of opioid receptor expression. Curr Opin Pharmacol (2002) 1.16
Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma. Oncologist (2009) 1.14
Phospholipase D1 corrects impaired betaAPP trafficking and neurite outgrowth in familial Alzheimer's disease-linked presenilin-1 mutant neurons. Proc Natl Acad Sci U S A (2006) 1.14